Health Affairs, 25, no. 2 (2006): 420-428 doi: 10.1377/hlthaff.25.2.420 © 2006 by Project HOPE	New Online   McAllen, TX & Beyond: An Expert Roundtable   Geography & Reform   Medicaid or Insurance Exchange?   Siren Song of New GME   Public Plan Option: Pro & Con

This Article Figures Only Full Text (HTML) Reprint (PDF) Submit a response to this article Comments: View responses Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (40) Citing Articles via Google Scholar Google Scholar Articles by Adams, C. P. Articles by Brantner, V. V. Search for Related Content PubMed PubMed Citation Articles by Adams, C. P. Articles by Brantner, V. V. Related Collections Legal/Regulatory Issues Business Of Health Pharmaceuticals Research And Technology Health Spending

Health Tracking

MarketWatch

Estimating The Cost Of New Drug Development: Is It Really $802 Million?

This paper replicates the drug development cost estimates of Joseph DiMasi and colleagues ("The Price of Innovation"), using their published cost estimates along with information on success rates and durations from a publicly available data set. For drugs entering human clinical trials for the first time between 1989 and 2002, the paper estimated the cost per new drug to be $868 million. However, our estimates vary from around $500 million to more than $2,000 million, depending on the therapy or the developing firm.

                      What's this?

This article has been cited by other articles:

				M. S. Boguski, K. D. Mandl, and V. P. Sukhatme Repurposing with a Difference Science, June 12, 2009; 324(5933): 1394 - 1395. [Abstract] [Full Text] [PDF]

				S. C. Johnston The 2008 William M. Feinberg Lecture: Prioritizing Stroke Research Stroke, December 1, 2008; 39(12): 3431 - 3436. [Abstract] [Full Text] [PDF]

				R. H. El-Maraghi and E. A. Eisenhauer Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III J. Clin. Oncol., March 10, 2008; 26(8): 1346 - 1354. [Abstract] [Full Text] [PDF]

				L. Yao and A. Rzhetsky Quantitative systems-level determinants of human genes targeted by successful drugs Genome Res., February 1, 2008; 18(2): 206 - 213. [Abstract] [Full Text] [PDF]

				T. Fiorino Industry, Clinical Trials, and the Cost of Cancer Drugs: An Investor's Perspective J. Clin. Oncol., July 1, 2007; 25(19): e21 - e23. [Full Text] [PDF]

				J. M. Hoffman, N. D. Shah, L. C. Vermeulen, G. T. Schumock, P. Grim, R. J. Hunkler, and K. M. Hontz Projecting future drug expenditures--2007 Am. J. Health Syst. Pharm., February 1, 2007; 64(3): 298 - 314. [Abstract] [Full Text] [PDF]

				N. J. Meropol and K. A. Schulman Cost of Cancer Care: Issues and Implications J. Clin. Oncol., January 10, 2007; 25(2): 180 - 186. [Abstract] [Full Text] [PDF]

				J. A. DiMasi and H. G. Grabowski Economics of New Oncology Drug Development J. Clin. Oncol., January 10, 2007; 25(2): 209 - 216. [Abstract] [Full Text] [PDF]

Comments: